Serum FT3/FT4 ratio may indicate the degree of T3 compensation in congenital hypothyroidism
- 1Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Abstract
Background: Clinical guidelines for hypothyroidism recommend measuring serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels as diagnostic and treatment efficacy indicators. However, they do not recommend measuring serum free triiodothyronine (FT3) levels because serum FT3 levels often remain within the normal range. However, serum TSH and FT4 levels alone make diagnosis and treatment decision-making difficult in conditions such as central hypothyroidism, suggesting the need for an additional indicator distinct from serum TSH levels. We investigated whether the serum FT3/FT4 ratio could be an indicator of congenital hypothyroidism (CH) severity, instead of serum TSH level. Methods: Thirty-seven newborns were diagnosed with CH (severe group (n = 13): serum TSH ≥ 30 mIU/L; moderate group (n = 24): serum TSH ≥ 5 to < 30 mIU/L). All infants in the severe group received thyroid hormone (TH) replacement therapy vs 13 infants in the moderate group (moderate group with CH). Serum TSH, FT4, FT3, and FT3/FT4 ratios were compared between each group and the two control groups of different ages at diagnosis and 2 months after treatment. Results: The serum FT3/FT4 ratio was elevated before treatment compared with the control group, reflecting CH severity. Two months after TH replacement, the serum FT3/FT4 ratio decreased significantly: severe group: at diagnosis, 0.48 vs 2 months, 0.27, p =<0.0001; moderate group with TH: 0.38 vs 2 months, 0.26, p < 0.0001. No change was observed in infants without TH replacement. Discussion: A high serum FT3/FT4 ratio in CH could reflect the degree of systemic T3 compensation and is an indicator of CH severity. This ratio may also be applicable in conditions in which serum TSH levels are not useful for diagnosis or when assessing treatment outcomes. Conclusion: A high serum FT3/FT4 ratio may be an indicator of hypothyroidism severity.
Related
- Thermodynamic Model and Experiments Indicate Kinetically Trapped States in Ionisable Lipid Nanoparticles
- Tracing of 13C-labeled fatty acids indicate the lack of linoleic acid synthesis in mammalian cells
- Taurine is a functional regulator of transthyretin; implication in transthyretin-induced hypothyroidism and amyloidosis
- Tracing the Putative Tissue Origin of Circulating Olfactory Receptor mRNAs in Gestational Hypothyroidism: Effects of Levothyroxine in Rats
- Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and C-Reactive Protein as Risk Markers in Thyroid Autoimmunity, Hypothyroidism, and Hyperthyroidism: A Cross-Sectional Study
BibTeX
@article{yamauchi2026serum,
title = {{Serum FT3/FT4 ratio may indicate the degree of T3 compensation in congenital hypothyroidism}},
author = {Takeru Yamauchi and Ami Keidai and Yutaro Tomobe and Seiichi Tomotaki and Kougoro Iwanaga and Junko Takita and Masahiko Kawai},
journal = {PLOS One},
year = {2026},
month = nov,
doi = {10.1371/journal.pone.0361192},
url = {https://doi.org/10.1371/journal.pone.0361192},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Serum FT3/FT4 ratio may indicate the degree of T3 compensation in congenital hypothyroidism
AU - Takeru Yamauchi
AU - Ami Keidai
AU - Yutaro Tomobe
AU - Seiichi Tomotaki
AU - Kougoro Iwanaga
AU - Junko Takita
AU - Masahiko Kawai
PY - 2026
DA - 2026/11/11
JO - PLOS One
DO - 10.1371/journal.pone.0361192
UR - https://doi.org/10.1371/journal.pone.0361192
AB - Background: Clinical guidelines for hypothyroidism recommend measuring serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels as diagnostic and treatment efficacy indicators. However, they do not recommend measuring serum free triiodothyronine (FT3) levels because serum FT3 levels often remain within the normal range. However, serum TSH and FT4 levels alone make diagnosis and treatment decision-making difficult in conditions such as central hypothyroidism, suggesting the need for an additional indicator distinct from serum TSH levels. We investigated whether the serum FT3/FT4 ratio could be an indicator of congenital hypothyroidism (CH) severity, instead of serum TSH level. Methods: Thirty-seven newborns were diagnosed with CH (severe group (n = 13): serum TSH ≥ 30 mIU/L; moderate group (n = 24): serum TSH ≥ 5 to < 30 mIU/L). All infants in the severe group received thyroid hormone (TH) replacement therapy vs 13 infants in the moderate group (moderate group with CH). Serum TSH, FT4, FT3, and FT3/FT4 ratios were compared between each group and the two control groups of different ages at diagnosis and 2 months after treatment. Results: The serum FT3/FT4 ratio was elevated before treatment compared with the control group, reflecting CH severity. Two months after TH replacement, the serum FT3/FT4 ratio decreased significantly: severe group: at diagnosis, 0.48 vs 2 months, 0.27, p =<0.0001; moderate group with TH: 0.38 vs 2 months, 0.26, p < 0.0001. No change was observed in infants without TH replacement. Discussion: A high serum FT3/FT4 ratio in CH could reflect the degree of systemic T3 compensation and is an indicator of CH severity. This ratio may also be applicable in conditions in which serum TSH levels are not useful for diagnosis or when assessing treatment outcomes. Conclusion: A high serum FT3/FT4 ratio may be an indicator of hypothyroidism severity.
SN - 1932-6203
ER -